The Detroit Cardiogenic Shock Initiative is an innovative collaboration between five hospitals in the Detroit area designed to improve outcomes in patients who experience cardiogenic shock after a heart attack. These hospitals all use the same best practices and protocols for treating cardiogenic shock. This protocol was developed using data from Abiomed’s Impella Quality (IQ) Assurance Database1. This protocol includes insertion of the Impella® heart pump before a percutaneous coronary intervention (PCI), staffing the hospital with physicians experienced in inserting Impella devices, and monitoring blood flow throughout the procedure.
Data was presented in March 2017 at the American College of Cardiology in Washington D.C. by the lead investigator, William W. O’Neill, MD, FACC, FSCAI, Medical Director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit. This study provides preliminary evidence that these protocols may successfully improve patient outcomes. Since the Detroit Cardiogenic Shock Initiative began, 37 patients have been treated for cardiogenic shock with the best practices protocol, and the survival rate of these patients was 84%. Moreover, all survivors returned home with their own hearts—no heart transplants or left ventricular assist devices (LVADs) were necessary. For comparison, the survival rate of cardiogenic shock patients before the Detroit Cardiogenic Shock Initiative started was 51%.
Dr. O’Neill remarked that “these results demonstrate the importance of circulatory support for survival and heart recovery in cardiogenic shock.” This study shows the promise of collaborations like the Detroit Cardiogenic Shock Initiative to provide data and implement best practices. There are plans to expand the Detroit model to other cities, and clinicians in Germany are using a similar protocol with similar initial results.
Abiomed continues to work towards better outcomes for patients with cardiogenic shock, including collaborating with clinicians and researchers across the country and around the world to develop best practices and protocols for treating shock and improve patient care.
- Learn more about the Detroit Cardiogenic Shock Initiative
- Learn more about Impella Best Practices
- Learn more about Complex Heart Disease
- Subscribe to our blog to learn more about heart and cardiovascular health
1Abiomed’s IQ Database is a collection of real-world, observational quality assurance data on over 95% of Impella patients since the Impella 2.5® heart pump’s introduction to the United States in 2008. The IQ database, combined with additional clinical data collected in the cVAD Registry™ and FDA pre- and post-market studies, is helping to identify best practices and protocols that are linked to the highest survival and native heart recovery rates at hospitals utilizing Impella heart pumps. The data contained in the IQ Assurance Database is useful in establishing certain trends associated with the use of Impella. The data contained therein is not pre-specified or statistically-powered and no statistical conclusions can be drawn from the hypothesis-generating information.
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: http://www.abiomed.com/important-safety-information